FANCA safeguards interphase and mitosis during hematopoiesis in vivo

Experimental Hematology

Volumn 43, Issue 12, 2015, Pages 1031-1046.e12

  Abdul Sater, Zahi ^a   Cerabona, Donna ^a   Potchanant, Elizabeth Sierra ^a   Sun, Zejin ^a   Enzor, Rikki ^a   He, Ying ^a   Robertson, Kent ^a   Goebel, W Scott ^a   Nalepa, Grzegorz ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FANCONI ANEMIA GROUP A PROTEIN; PACLITAXEL; FANCA PROTEIN, HUMAN; FANCA PROTEIN, MOUSE;

ARTICLE; CELL CYCLE ARREST; CHROMOSOME BREAKAGE; CYTOKINESIS; DNA CROSS LINKING; DNA DAMAGE; DRUG SENSITIVITY; EMBRYO; FANCA GENE; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE FUNCTION; GENOMIC INSTABILITY; HEMATOPOIESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; INTERPHASE; INTRACELLULAR SIGNALING; MICROSCOPY; MITOSIS; MITOSIS SPINDLE; MOUSE; NONHUMAN; PERICENTRIOLAR REGION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; ANIMAL; FANCONI ANEMIA; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY; SPINDLE APPARATUS;

ANIMALS; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP A PROTEIN; FEMALE; HEMATOPOIESIS; HUMANS; INTERPHASE; MALE; MICE; MICE, KNOCKOUT; MITOSIS; SPINDLE APPARATUS;

EID: 84961391910     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2015.08.013     Document Type: Article

References (96)

1. Kottemann M.C., Smogorzewska A. Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. Nature 2013, 493:356-363.
2. Rosenberg P.S., Alter B.P., Ebell W. Cancer risks in Fanconi anemia: Findings from the German Fanconi Anemia Registry. Haematologica 2008, 93:511-517.
3. Alter B.P., Giri N., Savage S.A., et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol 2010, 150:179-188.
4. Alter B.P. Fanconi anemia and the development of leukemia. Best Pract Res Clin Haematol 2014, 27:214-221.
5. D'Andrea A.D. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med 2010, 362:1909-1919.
6. Howlett N.G., Taniguchi T., Olson S., et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002, 297:606-609.
7. Sawyer S.L., Tian L., Kahkonen M., et al. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. Cancer Discov 2015, 5:135-142.
8. Jones S., Hruban R.H., Kamiyama M., et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009, 324:217.
9. Seal S., Thompson D., Renwick A., et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006, 38:1239-1241.
10. Narayan G., Arias-Pulido H., Nandula S.V., et al. Promoter hypermethylation of FANCF: Disruption of Fanconi anemia-BRCA pathway in cervical cancer. Cancer Res 2004, 64:2994-2997.
11. Taniguchi T., Tischkowitz M., Ameziane N., et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003, 9:5680574.
12. Tischkowitz M., Ameziane N., Waisfisz Q., et al. Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia. Br J Haematol 2003, 123:469-471.
13. Tischkowitz M.D., Morgan N.V., Grimwade D., et al. Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia. Leukemia 2004, 18:420-425.
14. Langevin F., Crossan G.P., Rosado I.V., Arends M.J., Patel K.J. Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice. Nature 2011, 475:53-58.
15. Garaycoechea J.I., Crossan G.P., Langevin F., Daly M., Arends M.J., Patel K.J. Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function. Nature 2012, 489:571-575.
16. Kim S., Hwang S.K., Lee M., et al. Fanconi anemia complementation group A (FANCA) localizes to centrosomes and functions in the maintenance of centrosome integrity. Int J Biochem Cell Biol 2013, 45:1953-1961.
17. Nalepa G., Enzor R., Sun Z., et al. Fanconi anemia signaling network regulates the spindle assembly checkpoint. J Clin Invest 2013, 123:3839-3847.
18. Zou J., Tian F., Li J., et al. FancJ regulates interstrand crosslinker induced centrosome amplification through the activation of polo-like kinase 1. Biol Open 2013, 2:1022-1031.
19. Zou J., Zhang D., Qin G., Chen X., Wang H., Zhang D. BRCA1 and FancJ cooperatively promote interstrand crosslinker induced centrosome amplification through the activation of polo-like kinase 1. Cell Cycle 2014, 13:3685-3697.
20. London N., Biggins S. Signalling dynamics in the spindle checkpoint response. Nat Rev Mol Cell Biol 2014, 15:736-747.
21. Naim V., Rosselli F. The FANC pathway and BLM collaborate during mitosis to prevent micro-nucleation and chromosome abnormalities. Nat Cell Biol 2009, 11:761-768.
22. Chan K.L., Palmai-Pallag T., Ying S., Hickson I.D. Replication stress induces sister-chromatid bridging at fragile site loci in mitosis. Nat Cell Biol 2009, 11:753-760.
23. Vinciguerra P., Godinho S.A., Parmar K., Pellman D., D'Andrea A.D. Cytokinesis failure occurs in Fanconi anemia pathway-deficient murine and human bone marrow hematopoietic cells. J Clin Invest 2010, 120:3834-3842.
24. Daniels M.J., Wang Y., Lee M., Venkitaraman A.R. Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science 2004, 306:876-879.
25. Mondal G., Rowley M., Guidugli L., Wu J., Pankratz V.S., Couch F.J. BRCA2 localization to the midbody by filamin A regulates cep55 signaling and completion of cytokinesis. Dev Cell 2012, 23:137-152.
26. Gordon D.J., Resio B., Pellman D. Causes and consequences of aneuploidy in cancer. Nat Rev Genet 2012, 13:189-203.
27. Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011, 144:646-674.
28. Bakhoum S.F., Compton D.A. Chromosomal instability and cancer: A complex relationship with therapeutic potential. J Clin Invest 2012, 122:1138-1143.
29. Chen M., Tomkins D.J., Auerbach W., et al. Inactivation of Fac in mice produces inducible chromosomal instability and reduced fertility reminiscent of Fanconi anaemia. Nat Genet 1996, 12:448-451.
30. Cammerer Z., Schumacher M.M., Kirsch-Volders M., Suter W., Elhajouji A. Flow cytometry peripheral blood micronucleus test in vivo: Determination of potential thresholds for aneuploidy induced by spindle poisons. Environ Mol Mutagen 2010, 51:278-284.
31. Balmus G., Karp N.A., Ng B.L., Jackson S.P., Adams D.J., McIntyre R.E. A high-throughput in vivo micronucleus assay for genome instability screening in mice. Nat Protoc 2015, 10:205-215.
32. Fenech M. Cytokinesis-block micronucleus cytome assay. Nat Protoc 2007, 2:1084-1104.
33. Palmer D.K., O'Day K., Trong H.L., Charbonneau H., Margolis R.L. Purification of the centromere-specific protein CENP-A and demonstration that it is a distinctive histone. Proc Natl Acad Sci USA 1991, 88:3734-3738.
34. Sigoillot F.D., Lyman S., Huckins J.F., et al. A bioinformatics method identifies prominent off-targeted transcripts in RNAi screens. Nat Methods 2012, 9:363-366.
35. Schuler M., Rupa D.S., Eastmond D.A. A critical evaluation of centromeric labeling to distinguish micronuclei induced by chromosomal loss and breakage in vitro. Mutat Res 1997, 392:81-95.
36. Brownlee C.W., Rogers G.C. Show me your license, please: Deregulation of centriole duplication mechanisms that promote amplification. Cell Mol Life Sci 2013, 70:1021-1034.
37. Godek K.M., Kabeche L., Compton D.A. Regulation of kinetochore-microtubule attachments through homeostatic control during mitosis. Nat Rev Mol Cell Biol 2015, 16:57-64.
38. O'Rourke B.P., Gomez-Ferreria M.A., Berk R.H., et al. Cep192 controls the balance of centrosome and non-centrosomal microtubules during interphase. PLoS One 2014, 9:e101001.
39. Lee K., Rhee K. PLK1 phosphorylation of pericentrin initiates centrosome maturation at the onset of mitosis. J Cell Biol 2011, 195:1093-1101.
40. Sdelci S., Schutz M., Pinyol R., et al. Nek9 phosphorylation of NEDD1/GCP-WD contributes to Plk1 control of gamma-tubulin recruitment to the mitotic centrosome. Curr Biol 2012, 22:1516-1523.
41. Joukov V., Walter J.C., De Nicolo A. The Cep192-organized aurora A-Plk1 cascade is essential for centrosome cycle and bipolar spindle assembly. Mol Cell 2014, 55:578-591.
42. Zimmerman W.C., Sillibourne J., Rosa J., Doxsey S.J. Mitosis-specific anchoring of gamma tubulin complexes by pericentrin controls spindle organization and mitotic entry. Mol Biol Cell 2004, 15:3642-3657.
43. Lawo S., Hasegan M., Gupta G.D., Pelletier L. Subdiffraction imaging of centrosomes reveals higher-order organizational features of pericentriolar material. Nat Cell Biol 2012, 14:1148-1158.
44. Mennella V., Agard D.A., Huang B., Pelletier L. Amorphous no more: Subdiffraction view of the pericentriolar material architecture. Trends Cell Biol 2014, 24:188-197.
45. Chandra S., Levran O., Jurickova I., et al. A rapid method for retrovirus-mediated identification of complementation groups in Fanconi anemia patients. Mol Ther 2005, 12:976-984.
46. Heinrich M.C., Hoatlin M.E., Zigler A.J., et al. DNA cross-linker-induced G2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint function. Blood 1998, 91:275-287.
47. Woods C.M., Zhu J., McQueney P.A., Bollag D., Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1995, 1:506-526.
48. Jordan M.A., Wendell K., Gardiner S., Derry W.B., Copp H., Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996, 56:816-825.
49. Torres K., Horwitz S.B. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 1998, 58:3620-3626.
50. Cuomo M.E., Knebel A., Morrice N., Paterson H., Cohen P., Mittnacht S. p53-Driven apoptosis limits centrosome amplification and genomic instability downstream of NPM1 phosphorylation. Nat Cell Biol 2008, 10:723-730.
51. Mikule K., Delaval B., Kaldis P., Jurcyzk A., Hergert P., Doxsey S. Loss of centrosome integrity induces p38-p53-p21-dependent G1-S arrest. Nat Cell Biol 2007, 9:160-170.
52. Crasta K., Ganem N.J., Dagher R., et al. DNA breaks and chromosome pulverization from errors in mitosis. Nature 2012, 482:53-58.
53. Dobles M., Liberal V., Scott M.L., Benezra R., Sorger P.K. Chromosome missegregation and apoptosis in mice lacking the mitotic checkpoint protein Mad2. Cell 2000, 101:635-645.
54. Van der Heijden M.S., Brody J.R., Dezentje D.A., et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 2005, 11:7508-7515.
55. Zhang C.Z., Spektor A., Cornils H., et al. Chromothripsis from DNA damage in micronuclei. Nature 2015, 522:179-184.
56. Mehta P.A., Harris R.E., Davies S.M., et al. Numerical chromosomal changes and risk of development of myelodysplastic syndrome-Acute myeloid leukemia in patients with Fanconi anemia. Cancer Genet Cytogenet 2010, 203:180-186.
57. Quentin S., Cuccuini W., Ceccaldi R., et al. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood 2011, 117:e161-e170.
58. Ceccaldi R., Parmar K., Mouly E., et al. Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell 2012, 11:36-49.
59. Ceccaldi R., Briot D., Larghero J., et al. Spontaneous abrogation of the G(2)DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients. J Clin Invest 2011, 121:184-194.
60. Woo H.I., Kim H.J., Lee S.H., Yoo K.H., Koo H.H., Kim S.H. Acute myeloid leukemia with complex hypodiploidy and loss of heterozygosity of 17p in a boy with Fanconi anemia. Ann Clin Lab Sci 2011, 41:66-70.
61. Ganem N.J., Godinho S.A., Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature 2009, 460:278-282.
62. Nam H.J., Naylor R.M., van Deursen J.M. Centrosome dynamics as a source of chromosomal instability. Trends Cell Biol 2015, 25:65-73.
63. Otsuki T., Nagashima T., Komatsu N., et al. Phosphorylation of Fanconi anemia protein, FANCA, is regulated by Akt kinase. Biochem Biophys Res Commun 2002, 291:628-634.
64. Sumara I., Gimenez-Abian J.F., Gerlich D., et al. Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr Biol 2004, 14:1712-1722.
65. Kupfer G.M., Yamashita T., Naf D., Suliman A., Asano S., D'Andrea A.D. The Fanconi anemia polypeptide, FAC, binds to the cyclin-dependent kinase, cdc2. Blood 1997, 90:1047-1054.
66. Thomashevski A., High A.A., Drozd M., et al. The Fanconi anemia core complex forms four complexes of different sizes in different subcellular compartments. J Biol Chem 2004, 279:26201-26209.
67. Kennedy R.D., Chen C.C., Stuckert P., et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 2007, 117:1440-1449.
68. Jacquemont C., Simon J.A., D'Andrea A.D., Taniguchi T. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin. Mol Cancer 2012, 11:26.
69. Maresca T.J., Salmon E.D. Welcome to a new kind of tension: Translating kinetochore mechanics into a wait-anaphase signal. J Cell Sci 2010, 123(Pt 6):825-835.
70. Barton J.C., Parmley R.T., Carroll A.J., et al. Preleukemia in Fanconi's anemia: Hematopoietic cell multinuclearity, membrane duplication, and dysgranulogenesis. J Submicrosc Cytol 1987, 19:355-364.
71. Willingale-Theune J., Schweiger M., Hirsch-Kauffmann M., Meek A.E., Paulin-Levasseur M., Traub P. Ultrastructure of Fanconi anemia fibroblasts. J Cell Sci 1989, 93(Pt 4):651-665.
72. Nalepa G., Clapp D.W. Fanconi anemia and the cell cycle: New perspectives on aneuploidy. F1000Prime Rep 2014, 6:23.
73. Choi E., Park P.G., Lee H.O., et al. BRCA2 fine-tunes the spindle assembly checkpoint through reinforcement of BubR1 acetylation. Dev Cell 2012, 22:295-308.
74. Maher C.A., Wilson R.K. Chromothripsis and human disease: Piecing together the shattering process. Cell 2012, 148:29-32.
75. Zhang C.Z., Leibowitz M.L., Pellman D. Chromothripsis and beyond: Rapid genome evolution from complex chromosomal rearrangements. Genes Dev 2013, 27:2513-2530.
76. Forment J.V., Kaidi A., Jackson S.P. Chromothripsis and cancer: Causes and consequences of chromosome shattering. Nat Rev Cancer 2012, 12:663-670.
77. Adamo A., Collis S.J., Adelman C.A., et al. Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia. Mol Cell 2010, 39:25-35.
78. Hess C.J., Ameziane N., Schuurhuis G.J., et al. Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia. Cell Oncol 2008, 30:299-306.
79. Xie Y., de Winter J.P., Waisfisz Q., et al. Aberrant Fanconi anaemia protein profiles in acute myeloid leukaemia cells. Br J Haematol 2000, 111:1057-1064.
80. Wang Z., Li M., Lu S., Zhang Y., Wang H. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway. Cancer Biol Ther 2006, 5:256-260.
81. Olopade O.I., Wei M. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell 2003, 3:417-420.
82. Wei M., Xu J., Dignam J., et al. Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat 2008, 111:113-120.
83. Neveling K., Kalb R., Florl A.R., et al. Disruption of the FA/BRCA pathway in bladder cancer. Cytogenet Genome Res 2007, 118:166-176.
84. Marsit C.J., Liu M., Nelson H.H., Posner M., Suzuki M., Kelsey K.T. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: Implications for treatment and survival. Oncogene 2004, 23:1000-1004.
85. Forbes S.A., Beare D., Gunasekaran P., et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015, 43(Database issue):D805-D811.
86. Ceccaldi R., Liu J.C., Amunugama R., et al. Homologous-recombination-deficient tumours are dependent on Poltheta-mediated repair. Nature 2015, 518:258-262.
87. Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
88. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
89. Chen C.C., Kennedy R.D., Sidi S., Look A.T., D'Andrea A. CHK1 inhibition as a strategy for targeting Fanconi anemia (FA) DNA repair pathway deficient tumors. Mol Cancer 2009, 8:24.
90. Forbes S.A., Beare D., Gunasekaran P., et al. COSMIC: Exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015, 43(Database issue):D805-D811.
91. Reva B., Antipin Y., Sander C. Predicting the functional impact of protein mutations: Application to cancer genomics. Nucleic Acids Res 2011, 39:e118.
92. Heinrich M.C., Hoatlin M.E., Zigler A.J., et al. DNA cross-linker-induced G2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint function. Blood 1998, 91:275-287.
93. Chandra S., Levran O., Jurickova I., et al. A rapid method for retrovirus-mediated identification of complementation groups in Fanconi anemia patients. Mol Ther 2005, 12:976-984.
94. Nalepa G., Enzor R., Sun Z., et al. Fanconi anemia signaling network regulates the spindle assembly checkpoint. J Clin Invest 2013, 123:3839-3847.
95. Crasta K., Ganem N.J., Dagher R., et al. DNA breaks and chromosome pulverization from errors in mitosis. Nature 2012, 482:53-58.
96. Zhang C.Z., Spektor A., Cornils H., et al. Chromothripsis from DNA damage in micronuclei. Nature 2015, 522:179-184.